Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04700176 · ClinicalTrials.gov registry record · Phase 2
A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma
A Phase 2 study, sponsored by Hackensack Meridian Health.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT04700176 is a Phase 2 study that was terminated before completion, run by Hackensack Meridian Health. The registered enrollment target is 1 participants.
The verdict
NCT04700176, a Phase 2 study, was terminated before completion, sponsored by Hackensack Meridian Health.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety and efficacy of the study drug daratumumab, when given together with Pomalidomide, Dexamethasone, and All-Transretinoic Acid (ATRA).
Interventions
- DRUG All-trans retinoic acid
- DRUG Dexamethasone
- DRUG Daratumumab
- DRUG Pomalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2022-05-02 |
| Est. Completion | 2023-11-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04700176
The ClinicalTrials.gov registry entry for NCT04700176 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hackensack Meridian Health, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which All-trans retinoic acid is the first listed.
NCT04700176 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04700176 about?
NCT04700176 is a clinical study titled "A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma". The purpose of this study is to test the safety and efficacy of the study drug daratumumab, when given together with Pomalidomide, Dexamethasone, and All-Transretinoic Acid (ATRA).
What is the current status of trial NCT04700176?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2022-05-02. Estimated completion is 2023-11-15.
What interventions are being tested in trial NCT04700176?
The interventions under investigation include: All-trans retinoic acid (DRUG), Dexamethasone (DRUG), Daratumumab (DRUG), Pomalidomide (DRUG).
Who is sponsoring clinical trial NCT04700176?
This trial is sponsored by Hackensack Meridian Health, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.